Video

Aerie COO: Expanding innovation of glaucoma therapeutics

Author(s):

OT Staff Reports
Conferences|GLAUCOMA 360

Tom Mitro, president, COO of Aerie Pharmaceuticals, discusses the key highlights from an industry panel discussion titled "Innovate without borders," held during the Glaucoma 360 New Horizons Forum, including the company's role in expanding into the global glaucoma therapeutics market.

See more Glaucoma 360 coverage

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
(Image credit: Ophthalmology Times) AGS 2025: Aqueous humor outflow improvement after excimer laser trabeculostomy with Clemens Strohmaier, PhD
Related Content
US News & World Report releases list of best ophthalmology ambulatory surgical centers in the US
March 18th 2025

US News & World Report releases list of best ophthalmology ambulatory surgical centers in the US

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Survey reveals gaps in patient awareness of preservative-free glaucoma treatments
March 14th 2025

Survey reveals gaps in patient awareness of preservative-free glaucoma treatments

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Genetic risk for glaucoma increases with age
March 8th 2025

Genetic risk for glaucoma increases with age

New analysis on Mont Blanc Phase 3 trial for NCX 470 for patients with OAG released by Nicox
March 7th 2025

New analysis on Mont Blanc Phase 3 trial for NCX 470 for patients with OAG released by Nicox

© 2025 MJH Life Sciences

All rights reserved.